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Abstract 
 
Objectives: Dermatomyositis and Polymyositis are rare chronic inflammatory disorders with 
significant associated morbidity and mortality despite treatment.  High-dose corticosteroids 
in addition to other interventions such as immunosuppressants, immunomodulators and, 
more recently, biologics, are commonly used in clinical practice, however there are no clear 
guidelines directing their use. Our objective was to systematically review the evidence for 
immunotherapy in the treatment of dermatomyositis and polymyositis.  
Methods: Relevant studies were identified through Embase and PubMed database searches.  
Trials were selected using pre-determined selection criteria and then assessed for quality. 
Randomized controlled trials and experimental studies without true randomization and 
including adult patients with definite or probable dermatomyositis or polymyositis were 
evaluated.  Any type of immunotherapy was considered. Clinical improvement, judged by 
assessment of muscle strength after 6 months, was the primary outcome.  Secondary 
outcomes included IMACS definition of improvement, improvements in patient and 
physician global scores, physical function and muscle enzymes.   
Results: Twelve studies met eligibility criteria. Differences in trial design, quality, and 
variable reporting of baseline characteristics and outcomes made direct comparison 
impossible.  Although no treatment can be recommended on the basis of this review, 
improved outcomes were demonstrated with a number of agents including methotrexate, 
azathioprine, ciclosporin, rituximab and intravenous immunoglobulin. Plasmapheresis and 
leukapheresis were of no apparent benefit.  
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Conclusion: More high-quality randomized controlled trials are needed to establish the role 
of immunosuppressive agents in the treatment of these conditions and the clinical context in 
which they are most likely to be beneficial. 
 
 4 
Introduction 
 
Polymyositis and dermatomyositis are rare chronic inflammatory disorders of muscle, 
characterized by subacute onset of proximal muscle weakness, elevated muscle enzymes 
and inflammatory infiltrates on muscle biopsy.  Characteristic cutaneous lesions are found in 
dermatomyositis.  These conditions may occur in association with other autoimmune 
connective tissue diseases and there is significant overlap between the two diseases.   
 
Treatment of inflammatory myopathies is generally empirical and subject to the experience 
of the treating physician.  Despite having only recently been evaluated in the context of a 
randomized controlled clinical trial, glucocorticoids are the only FDA approved agents for 
treatment of these conditions and are generally accepted as being effective. As a substantial 
number of patients do not respond to glucocorticoids alone, additional agents such as 
immunosuppressants, immunomodulators, and, more recently, biologics, are commonly 
used in clinical practice.  However, there are no evidence based guidelines to direct 
prescribing.  Here we systematically review the evidence for immunotherapy in the 
treatment of dermatomyositis and polymyositis. 
 
Materials and methods 
Methods of analysis and eligibility criteria were specified in advance. The study conforms to 
the PRISMA statement for reporting systematic reviews and meta-analyses of studies that 
evaluate healthcare interventions.(1)  
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Search strategy 
The search date was 4th February 2015. Potentially relevant citations were identified through 
Embase and PubMed database searches.  The terms ‘polymyositis’, dermatomyositis’, 
‘myositis’ and ‘idiopathic inflammatory myopathy’ were combined and searched in 
conjunction with the following terms: corticosteroid, glucocorticoid, prednisolone, 
methotrexate, azathioprine, ciclosporin (cyclosporine A), cyclophosphamide, 
immunoglobulin, interferon, leflunomide, mycophenolate, plasma exchange, 
plasmapheresis, biologic, anti-tumour necrosis factor alpha, infliximab, etanercept, 
rituximab, and anakinra.  Randomized controlled trial filters were used as described by the 
Cochrane collaboration.(2) Authors scrutinized the titles and abstracts to identify all relevant 
studies.  Reference lists of relevant studies and related reviews were hand-searched to 
identify other potentially relevant citations. 
 
Selection criteria 
The following criteria were used to select studies for evaluation: the study was a randomized 
controlled trial or experimental study without true randomization (quasi-randomized study); 
the patients studied were adults (>18 years of age) with a diagnosis of definite or probable 
dermatomyositis or polymyositis according to either the Bohan and Peter(3, 4) or Dalakas (5) 
classification criteria; the study participants were judged to have active disease; and any 
type of immunotherapy was considered. The final inclusion and exclusion decisions were 
made after examining the full texts of all potentially relevant citations. Relevant data were 
extracted and analyzed and the results summarized in text and tables in three main 
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categories: study characteristics, baseline characteristics of study participants and outcomes. 
Trials were scored for quality using the Jadad scoring system.(6) 
 
Outcome  
The primary outcome was improvement in muscle strength, ideally after 6 months. 
Secondary outcomes included improvements in patient and physician global scores, physical 
function and muscle enzymes, and adverse events, in addition to achieving the International 
Myositis Assessment and Clinical Studies group (IMACS) Definition of Improvement (DOI) 
after at least 6 months. This combines a core set of six disease activity measures (physician 
global score, patient global score, muscle strength, physical function, muscle enzymes and 
extra-muscular involvement) and defines a clinically meaningful change for each.(7)   
 
Statistical analysis 
Results were analyzed using Review Manager 5.1 software (Cochrane Collaboration, Oxford, 
UK).  The Cochran-Mantel-Haenszel chi-squared method was used to analyze dichotomous 
data and inverse variance was used for continuous data. Where possible, a Forest plot was 
created, using a random effects model, to display graphically the effect size and confidence 
interval of the effect. A P-value of <0.05 was considered statistically significant.  As few 
studies were included in this review, and because there were significant differences in the 
study designs, populations, interventions and outcomes, meta-analysis and measurement of 
summary effects was not always possible.  
 
Results 
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Search results 
The preliminary search identified 2344 studies which were assessed for relevance.  Thirteen 
were selected as potentially relevant, and one further relevant study was identified through 
hand-searching the reference lists of relevant studies.  One previous systematic review on 
the topic was found.(8) Three studies were excluded after full assessment (one was an 
abstract with insufficient detail to fully assess against the selection criteria, one a follow-up 
study of an included trial and the other terminated early with only two participants reaching 
the primary endpoint).  Eleven studies evaluating a total of 464 patients were included for 
further analysis. Figure 1 displays the flow of study selection and the characteristics of the 
included and excluded studies are summarized in Table 1. 
 
Baseline characteristics 
The baseline patient characteristics are summarized in Table 2.  The average age across 
treatment groups ranged from 36 to 55 years, and the proportion of females ranged from 47 
to 92%.  Disease duration ranged from less than six months to more than five years, 
reflecting the inclusion of patients with refractory or relapsed myositis in a number of trials.  
Baseline muscle strength was reported in a number of ways.  Most trials (9-16) used manual 
muscle testing (MMT) of various numbers of muscles or pairs of muscles, to give a 
summative score out of a total maximum.  Vencovsky et al.(17) used a muscle endurance 
and function test (MEFT) with a maximum score of 56.  Hollingworth et al.(18) used a 
composite score of muscle strength, muscle biopsy, electromyogram (EMG) and CK.  
 
Responses 
 8 
Table 3 summarizes the main outcomes of each study. 
 
Improvements in muscle strength 
Statistically significant improvements in muscle strength at 3 months were observed by 
Dalakas et al.(11) in the group receiving IVIg.  However, this result was not reproduced by 
Miyasaka et al.(19)  Although the group receiving IVIg showed numerically greater changes 
in MMT at 8 weeks than the placebo group, the differences were not statistically significant. 
Median time to improvement in muscle strength was shorter in the IVIg group, but this did 
not reach statistical significance.   
 
Vencovsky et al.(17) (CsA and MTX group) demonstrated no significant difference between 
the CsA and MTX groups and, while significant improvements in muscle strength were 
demonstrated in all treatment groups by Ibrahim et al. (MTX, CsA and combination 
MTX/CsA), intention to treat analyses did not demonstrate any significant treatment effects. 
Hollingworth et al.(18) reported a non-significant trend towards benefit with ALG/AZA 
combination therapy compared to placebo, but incomplete outcome data reporting made 
calculation of effect size impossible.  Villalba et al.(12) reported a non-significant trend 
towards benefit with combination MTX/AZA compared to IV MTX. Bunch et al. concluded 
that there was no benefit adding AZA to prednisolone at three months, (16) however, the 
long-term follow-up data showed a significant reduction in functional disability in the AZA 
group compared to the group given prednisolone alone.(20) Miller et al. reported no 
improvement in strength with either plasmapheresis or leukapheresis. (21)  Oddis et al. 
demonstrated no significant difference in time to achieve a 20% improvement in MMT-8 
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between the early vs. late Rituximab groups.(9) Only 6 studies (9, 10, 12, 13, 15, 17) 
measured muscle strength at or after 6 months. 
 
Physical function 
Physical function was reported in seven studies. (11-15, 21)  A number of measurement 
tools were used, including activities of daily living (ADL) score, based either on the modified 
Convery Assessment Scale (22) adapted for myositis or the Barthel Index,(23) the physical 
component of the Short Form 36 (SF-36),The Amyotrophic Lateral Sclerosis Functional rating 
Scale (24) and the Health Assessment Questionnaire (HAQ).   A 9% significant improvement 
in functional rating scale was reported by Ibrahim et al. for all treatment groups (MTX, CsA 
and combination MTX/CsA) but these became non-significant in intention to treat 
analyses.(10) A non-significant trend towards benefit was noted by Villalba et al. in the 
group receiving combination MTX/AZA compared to IV MTX.(12)  Dalakas et al. reported an 
improvement in ADL score from 65 (low) to 100 (normal) in the patients responding to IVIg, 
but no data were given for either the non-responders or placebo group,(11) and Miyasaka et 
al. reported numerically greater improvements in ADL scores in the IVIg group compared to 
placebo, but the difference was not statistically significant.(14)  Numerically greater, 
although statistically insignificant, decreases in HAQ score were found in the patients 
receiving Etanercept compared to placebo(15) and van de Vlekkert et al. noted similar SF-36 
scores in both the prednisolone and dexamethasone groups.(13)  There was no evidence of 
improvement in patients receiving PEX or leukapheresis.(25) 
 
Muscle enzymes 
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Muscle enzymes were reported in 8 studies.(10, 13-18, 25) No difference in CK was seen at 
12 months in intention to treat analyses of MTX, CsA or combination MTX/CsA compared to 
glucocorticoids alone. There was no significant difference in the time to achieve normal 
muscle enzymes when comparing AZA and prednisolone to prednisolone alone at 3 
months.(16)  Long-term follow-up of these patients demonstrated a non-significant trend 
towards lower CK in the patients taking both prednisolone and AZA.(20)  Hollingworth et al. 
reported a more marked improvement in CK in the group receiving IIS compared to the 
group receiving prednisolone alone.(18)  When compared to baseline values, significant 
reductions in CK were noted in patients receiving PEX or leukapheresis but not sham 
apheresis,(21) and in patients given MTX or CsA in addition to prednisolone.(26)  In the IVIg 
study where this outcome is reported, both placebo and treatment groups demonstrated 
significant reductions in CK when compared to baseline.(14) Similar improvements in CK 
were demonstrated in both prednisolone and dexamethasone groups (13) and Etanercept 
and placebo groups.(15)   
 
Patient and physician global scores 
Only two trials reported patient global scores as an outcome.(15, 17) Significant 
improvements were noted in patients receiving both MTX and CsA at 3 and 6 months when 
compared to baseline.(17)  Similar improvements were noted in both Etanercept and 
placebo groups.(15)  Only one trial reported physician global scores as an outcome: 
numerically greater improvements were noted in the Etanercept group when compared to 
placebo, but the difference was not statistically significant.(15)  
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IMACS Definition of Improvement 
Only Oddis et al used this as an outcome measure. The use of Rituximab at weeks 0 and 1 in 
refractory patients failed to result in any significant improvement in time to DOI compared 
to Rituximab at weeks 8 and 9, or the proportion of patients achieving DOI at week 8 (end of 
placebo controlled phase). Despite this, 83% patients met DOI by the end of study evaluation 
and the mean prednisolone dose reduced significantly from baseline.(9) Changes in core set 
measures, including all those discussed above, were reported as being non-significant 
between the two intervention groups and data for each measure were not reported by the 
authors, however, they did report a reduction in mean/median scores over the follow-up 
period.(9) Later sub-analysis of this study showed that the presence of anti-synthetase or 
anti-Mi2 autoantibodies, juvenile onset disease and lower disease damage scores was highly 
predictive of achieving improvement following Rituximab.(27) 
 
Safety and tolerability 
Azathioprine Bunch et al. reported 2 withdrawals in the AZA group because of toxicity 
(intolerable GI side effects, pneumonitis).(16) None of the AZA-treated patients developed 
skin rash, oral ulceration, pulmonary disease, elevated liver enzymes, blood dyscrasias or 
renal abnormalities during the extended follow-up period.(20) 
Villalba et al. reported a total of 11 withdrawals from the combination MTX/AZA treatment 
arm (6/15 during initial phase, 5/13 during crossover phase) for inefficacy or toxicity.  Severe 
GI intolerance was the commonest cause of withdrawal (6 patients); there was 1 case of 
severe infection.(12) It is assumed that the remaining withdrawals were because of 
inefficacy.  Overall, 36% of patients did not complete oral combination therapy.  There was 
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no significant difference in the number of withdrawals when compared to the IV MTX 
group.(12)  
 
Hollingworth et al. reported 14 withdrawals due to side effects.  These were all fully 
reversible and known potential side effects.(18) Withdrawals were reported according to 
trial drug rather than subgroup, so these figures include patients with systemic lupus 
erythematosus, polyarteritis nodosa and myositis who were treated with the AZA/ALG 
combination.  
 
Methotrexate Villalba et al. reported 11 withdrawals from the IV MTX treatment arm (7/15 
during the initial phase, and 4/11 during the crossover phase).  Four patients were 
withdrawn because of drug toxicity (GI intolerance, severe infection, rash, elevated liver 
enzymes) and 1 was withdrawn because of poor intravenous access.(12)  It is assumed that 
the remaining 6 were withdrawn because of inefficacy.  Overall, 61% of patients did not 
complete IV therapy.  GI side effects were the commonest reason for discontinuation in the 
oral AZA/MTX arm (see under Azathioprine).(12)  Lack of efficacy was noted in 16 patients 
receiving IV MTX and 8 patients receiving oral combination AZA/MTX.(12) 
Vencovsky et al. reported 4 withdrawals from the oral MTX treatment arm due to toxicity 
(pancytopaenia, gut perforation, alveolitis, petechiae). None were withdrawn because of 
inefficacy.(17) Ibrahim et al reported 3 withdrawals from the MTX arm: 1 due to inefficacy, 1 
due to toxicity, and 1 due to patient choice; 3 further patients were lost to follow-up. These 
6 patients represent 50% of those enrolled in the MTX arm. In the same study, 3 patients 
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were withdrawn from the MTX/CSA arm: 2 due to toxicity and 1 to patient choice, with 1 
further lost to follow-up, therefore only 74% completed combination therapy.(10)  
 
Ciclosporin Vencovsky et al. reported 2 withdrawals because of toxicity (renal impairment, 
severe infection) and none for inefficacy.  One patient was lost to follow-up.(17) Ibrahim et 
al. reported withdrawal in 1 patient because of toxicity and 3 due to patient choice, 1 other 
patient was lost to follow-up (31% enrolled).(10) 
 
Rituximab Oddis et al. reported only one withdrawal due to an adverse event. Twenty-six 
serious adverse events were reported during the trial period, infections being the most 
common.(9) There were no differences in adverse events at week 8 (the randomized placebo 
controlled time point).(9) Predictably, infusion reactions were significantly more common in 
the Rituximab group compared to placebo: 2 events required hospitalization and 7 of 60 
patients were not able to receive the full dose of Rituximab.(9) It is noteworthy that no 
glucocorticoids were administered at the time of study medication infusion, which may have 
influenced the incidence and seriousness of infusion reactions. 
 
Plasma exchange and leukapheresis Miller et al. reported 1 withdrawal from the PEX arm 
due to deteriorating disease, and no improvement in 9 of the 13 treated patients.  The 
condition of 3 of the 13 patients treated with leukapheresis deteriorated, and there was no 
change in the condition of 7.  No patients were withdrawn from either arm because of 
toxicity, although the rate of adverse events in both arms was high.(21) 
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Intravenous immunoglobulin Dalakas et al. reported no withdrawals for inefficacy or toxicity 
in either the IVIg or placebo arm.  IVIg was well tolerated, with the only reported adverse 
event being severe headache, which occurred in 2 patients and required treatment with 
opiate analgesics.(11) Miyasaka et al., in contrast, reported adverse drug reactions in 42.3% 
of patients with two serious events in one patient (increased CK and muscle weakness) 
which they deemed probably related to IVIg.(14) 
 
Anti-lymphocyte globulin Hollingworth et al. reported 5 withdrawals due to toxicity.  
Common side effects included drug fevers and rashes, but 75% completed the course of 
ALG.(18)  Again, these figures include all patients given ALG/AZA combination therapy, 
rather than the myositis patients only.  Withdrawals due to inefficacy were not reported.(18) 
 
Discussion 
There is a lack of good quality clinical trials assessing treatment approaches in patients with 
IIM. Many of the trials that do exist assess treatment response in patients with refractory 
disease, who have failed to respond to conventional therapy either with corticosteroids 
alone or with additional Immunosuppression. (9-12, 14, 16, 18, 21) This may have 
implications when trying to apply the results to treatment naïve patients at diagnosis. 
Furthermore, idiopathic inflammatory myositis is an umbrella term encompassing a 
heterogenous group of diseases that is far from clearly defined by the subgroups 
dermatomyositis and polymyositis. While many of the included studies failed to 
demonstrate statistically significant improvements, this may be because of differential 
treatment responses between myositis subsets, as demonstrated by sub-analysis of the 
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rituximab trial.(27) Only one other paper analyzed the distribution of myositis-specific and 
myositis-associated autoantibodies between the two treatment groups, but the impact of 
the presence of various autoantibodies on outcome and response to treatment was not 
assessed.(17)  Future studies should take into account the association of certain myositis-
specific autoantibodies and responsiveness to therapy.(28) 
 
Plasmapheresis and leukapheresis were of no apparent benefit and resulted in improvement 
in muscle enzymes but no other parameters assessed. Although muscle enzymes are used as 
an outcome measure in treatment of these conditions, it must be remembered that enzyme 
levels alone are an inadequate measure of clinical response in myositis, and active 
inflammation, as demonstrated on muscle biopsy or MRI, can be demonstrated in the setting 
of normal muscle enzymes. 
 
IVIg is the only agent that has been demonstrated to have statistically significant benefit 
compared to placebo when used in the treatment of refractory myositis.(11)  
Disappointingly, a subsequent placebo controlled trial of IVIg did not reproduce these 
findings; the authors cite potential steroid carry-over effects, possible steroid myopathy and 
a small study population as potential explanations.(14) Given the different study locations 
and that Dalakas et al. exclusively enrolled patients with dermatomyositis whereas 
Miyasaka et al. included both dermatomyositis and polymyositis patients, it is also possible 
that differential treatment responses of myositis subsets or patient ethnicity influenced 
study outcomes. It should also be noted that these two studies used different IVIg 
formulations and dosing regimens.(11, 14)  
 16 
 
Whilst the placebo controlled trial of AZA did not show any significant evidence of benefit at 
3 months, long-term follow-up data did suggest benefits and patients treated with AZA were 
stronger and required less steroid than the group treated with steroids alone.(16, 20) The 
impact of all agents must be considered in light of the well-known detrimental side effects of 
long-term glucocorticoid exposure.  Although the Oddis et al. study did not meet its end 
point, this study did demonstrate a significant steroid sparing effect with a statistically 
significant fall in prednisolone dose from baseline to the end point of the trial.(9) In contrast, 
Ibrahim et al. demonstrated no difference at the end of their trial in mean daily prednisolone 
dose between the placebo group and the different treatment groups. (10) 
 
While the earlier study comparing MTX to CsA demonstrated significant improvement in 
muscle strength and function in both patient groups (no treatment was superior to the 
other), (17) Ibrahim et al. demonstrated no difference in intention to treat analyses for MTX, 
CsA or combination MTX/CsA compared to placebo.(10) The later study had a high 
proportion of patients discontinue or lost to follow-up (26-50% in each arm) and 24% 
(14/58) withdrew due to adverse events, suggesting either that these medications are poorly 
tolerated by many patients or that any perceived benefit is outweighed by side-effects.  
In other trials comparing the traditional immunosuppressants, MTX was found to be better 
tolerated than either AZA or CsA.(17, 29) The relatively low cost of oral MTX, its acceptable 
safety profile and familiarity with its use in other rheumatic diseases are further advantages. 
Based on the recent Ibrahim et al. study, continued use of these agents is called into 
question, however it may be that the appropriate context needs to be more clearly defined: 
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patients in the Ibrahim et al. study had active disease despite steroid therapy but when the 
same agents were used in newly diagnosed children with juvenile dermatomyositis the 
results clearly favoured combination treatment, and MTX had a better safety profile 
compared to CsA.(30) While the evidence for use of these agents remains limited, they 
continue to be widely prescribed for a variety of myositis presentations. (31) 
 
This systematic review has a number of limitations, mainly related to the number, quality 
and design of the studies analyzed.  There are very few published randomized controlled 
trials in dermatomyositis and polymyositis and most literature regarding treatment of these 
rare conditions is in the form of case series and expert opinion.  Of the studies that were 
selected for review, there were significant differences in study design and quality.  Various 
outcome measures were used and were not directly comparable, and follow-up periods 
ranged widely.  Furthermore, although all study participants were judged to have ‘active 
disease’, disease duration and previous treatments varied greatly.  In addition, there was 
significant diversity in the range of treatments studied, with some treatments not being 
commonly used in clinical practice, e.g. ALG and IV MTX.  This is unlikely to change, as there 
are a vast number of unstudied or inadequately studied potential treatment modalities for 
these rare conditions, including not only the traditional immunosuppressants, but also an 
ever-expanding repertoire of biologic agents.  
 
Despite the fact that myositis is a rare disease it is remarkable that so few articles were 
deemed suitable for sub-review. The deficiency of good quality therapeutic trials in 
polymyositis and dermatomyositis is underlined here, and evidence-based prescribing 
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recommendations are not yet possible for these rare and difficult diseases. Such a result 
emphasises the ongoing need for national, multicentre randomised controlled clinical trials, 
particularly in treatment naive cases. 
 
 
Acknowledgements 
 
 
Conflicts of interest 
The authors declare they have no conflicts of interest 
 
Funding 
Sarah Tansley is supported by a fellowship funded by the Bath Institute for Rheumatic 
Diseases
 19 
 
References 
1. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The 
PRISMA statement for reporting systematic reviews and meta-analyses of studies that 
evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical research ed). 
2009;339:b2700.  
2. Higgins JPT GS. Cochrane Handbook for Systematic Reviews of Interventions: The 
Cochrane Collaboration; 2011. Available from: www.cochrane-handbook.org. 
3. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J 
Med. 1975;292:344-7.  
4. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J 
Med. 1975;292:403-7. 
5. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J 
Med. 1991;325:1487-98.  
6. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. 
Assessing the quality of reports of randomized clinical trials: is blinding necessary? 
Controlled clinical trials. 1996;17:1-12.  
7. Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, et al. 
International consensus on preliminary definitions of improvement in adult and juvenile 
myositis. Arthritis Rheum. 2004;50:2281-90.  
8. Gordon PA, Winer JB, Hoogendijk JE, Choy EH. Immunosuppressant and 
immunomodulatory treatment for dermatomyositis and polymyositis. The Cochrane 
database of systematic reviews. 2012;8:CD003643.  
9. Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al. 
Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult 
polymyositis: A randomized, placebo-phase trial. Arthritis Rheum. 2013;65:314-24. 
10. Ibrahim F, Choy E, Gordon P, Dore CJ, Hakim A, Kitas G, et al. Second-line agents in 
myositis: 1-year factorial trial of additional immunosuppression in patients who have 
partially responded to steroids. Rheumatology. 2014; Epub ahead of print 
11. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al. A controlled 
trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. 
N Engl J Med. 1993;329:1993-2000. 
12. Villalba L, Hicks JE, Adams EM, Sherman JB, Gourley MF, Leff RL, et al. Treatment of 
refractory myositis. A randomized crossover study of two new cytotoxic regimens. Arthritis 
Rheum. 1998;41:392-9. 
13. van de Vlekkert J, Hoogendijk JE, de Haan RJ, Algra A, van der Tweel I, van der Pol WL, 
et al. Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset 
myositis, a randomised clinical trial. Neuromuscul Disord. 2010;20:382-9. 
14. Miyasaka N, Hara M, Koike T, Saito E, Yamada M, Tanaka Y. Effects of intravenous 
immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis 
resistant to corticosteroids: A randomized double-blind placebo-controlled trial. Mod 
Rheumatol. 2012;22:382-93. 
15. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol. 2011;70:427-
36.  
16. Bunch TW, Worthington JW, Combs JJ, Ilstrup DM, Engel AG. Azathioprine with 
prednisone for polymyositis. A controlled, clinical trial. Ann Int Med. 1980;92:365-9.  
 20 
17. Vencovsky J, Jarosova K, Machacek S, Studynkova J, Kafkov J, Bartunkov J, et al. 
Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. 
Scand J Rheumatol. 2000;29:95-102. 
18. Hollingworth P, de Vere Tyndall A, Ansell BM, Platts-Mills T, Gumpel JM, Mertin J, et 
al. Intensive immunosuppression versus prednisolone in the treatment of connective tissue 
diseases. Ann Rheum Dis. 1982;41:557-62.  
19. Amemiya K, Semino-Mora C, Granger RP, Dalakas MC. Downregulation of TGF-beta1 
mRNA and protein in the muscles of patients with inflammatory myopathies after treatment 
with high-dose intravenous immunoglobulin. Clin Immunol. 2000;94:99-104.  
20. Bunch TW. Prednisone and azathioprine for polymyositis: long-term followup. 
Arthritis Rheum. 1981;24:45-8.  
21. Miller FW, Leitman SF, Cronin ME, Hicks JE, Leff RL, Wesley R, et al. Controlled trial of 
plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med. 
1992;326:1380-4. 
22. Convery FR, Minteer MA, Amiel D, Connett KL. Polyarticular disability: a functional 
assessment. Arch Phys Med Rehabil. 1977;58:494-9.  
23. Mahoney FI, Barthel DW. Functional Evaluation: The Barthel Index. Maryland state 
medical journal. 1965;14:61-5.  
24. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of 
daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study 
(ACTS) phase I-II Study Group. Arch Neurology. 1996;53:141-7.  
25. Miller FW, Leitman SF, Cronin ME, Hicks JE, Leff RL, Wesley R, et al. Controlled trial of 
plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med. 
1992;326:1380-4.  
26. Vencovsky J, Jarosova K, Machacek S, Studynkova J, Kafkova J, Bartunkova J, et al. 
Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. 
Scand J Rheumatol. 2000;29:95-102.  
27. Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, et al. 
Predictors of clinical improvement in rituximab-treated refractory adult and juvenile 
Dermatomyositis and adult polymyositis. Arthritis Rheum. 2014;66:740-9. 
28. Joffe MM, Love LA, Leff RL, Fraser DD, Targoff IN, Hicks JE, et al. Drug therapy of the 
idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, 
and methotrexate and a comparison of their efficacy. The American journal of medicine. 
1993;94:379-87.  
29. Miller J WY, Saminaden S , Lecky BRF, Winer JB. Randomised double blind controlled 
trial of methotrexate and steroids compared with azathioprine and steroids in the treatment 
of idiopathic inflammatory myopathy. J Neurol Sci. 2002;199(Suppl 1):S53. 
30. Ruperto N, Pistorio A, Knupp Feitosa de Oliveira S, Cuttica R, Ravelli A, Fischbach M, 
et al. A randomized trial in new onset juvenile dermatomyositis: prednisone versus 
prednisolone plus cyclosporine versus prednisone plus methotrexate. Pediatric 
Rheumatology. 2013;11(Suppl 2):O19. 
31. Tansley SL, Sharp C, McHugh N, Christopher-Stine L, Chinoy H. 181. Developing 
Standardized Treatment for Adults with Myositis and Different Phenotypes. Rheumatology. 
2014;53(suppl 1):i127. 
 
 
 21 
 
Figure 1. Study selection in the systematic review 
 
  
Table 1. A summary of studies short-listed for review 
Short-listed studies are generally small, they assess a range of treatment options and use a variety of different outcome measures. 
 
Study Year Design Cases PM/DM/ 
Both 
Intervention Outcome Follow-up Jadad score 
Corticosteroids 
van de Vlekkert 
et al. 
2010 Double-
blind RCT 
62 Both Pred vs 
Dex 
MMT15, CK, SF-36, 
neuromuscular symptom score, 
extramuscular features 
18 months 5 
Immunosuppressants 
Bunch et al. 1980 Double-
blind RCT 
16 PM Pred + AZA vs 
Pred + PBO 
MMT18, CK, muscle biopsy 3 months 3 
Bunch et al. a 1981 Unblinded 
follow-up 
of RCT 
16 PM Pred + AZA vs 
Pred + PBO 
Muscle strength, prednisolone 
dose, CK 
1 & 3 years 2 
Hollingworth et 1982 Randomize 14 Both ALG + AZA + Pred Composite score of strength, 2 years 2 
  
al. d open-
label 
crossover 
vs 
Pred 
muscle biopsy, EMG, CK 
Miller et al. a 2002 Double-
blind RCT 
28 Both Pred + AZA vs 
Pred + MTX 
Myometry, functional 
assessment, VAS 
1 year 2 
Villalba et al. 1998 Randomize
d open-
label 
crossover 
30 Both 
(Refractory) 
Pred + MTX + AZA 
vs 
Pred + IV MTX 
Strength/function score, MMT16, 
ADL score, CK 
3 & 6 months 2 
Vencovsky et al. 2000 RCT 36 Both Pred + CsA vs 
Pred + MTX 
MEFT, patient global, MRI, CK, 
serum IL-1Ra 
1, 3 & 6 
months 
3 
Ibrahim et al 2014 Double-
blind 
placebo 
controlled 
RCT 
58 Both MTX,  CsA, MTX + 
CsA, PBO 
MMT, functional rating scale, 
30m walk time, creatinine kinase, 
ESR 
12, 28, 40, 56 
weeks 
5 
  
Biologic agents 
Hengstman et al.a 2007 Open-label 
controlled 
trial 
6 Both Infliximab + MTX vs 
MTX 
MMT8, dynamometry,  patient 
global, physician global 
6 months 1 
The Muscle Study 
Group. 
2011 Double-
blind RCT 
16 DM Pred + ETAN vs 
Pred + PBO 
MMT26, myometry, CK, disease 
activity, patient & physician 
global, physical function, 
cutaneous manifestations, quality 
of life 
1 year 4 
Oddis et al 2013  Double-
blind 
placebo 
contolled 
RCT 
200 Both & JDM 
(refractory) 
Rituximab late or 
early 
IMACS DOI, 20% improvement in 
MMT8 
14 visits over 
44 weeks 
5 
Other 
  
Dalakas et al. 1993 Double-
blind RCT 
(crossover) 
15 DM 
(Refractory) 
IVIg vs 
PBO 
MMT18, neuromuscular 
symptom score, ADL score, CK, 
muscle biopsy 
3 & 6 months 5 
Miyasaka et al. 2011 Double-
blind RCT 
(crossover) 
26 Both 
(Steroid-
resistant) 
IVIg vs 
PBO 
MMT18, CK, ADL score 8, 16, 20 
weeks 
4 
Miller et al. 1992 Double-
blind RCT 
39 Both PEX vs 
Leukapheresis vs 
Sham apheresis 
MMT, ADL score, CK 1 month 4 
 
a. Excluded  
ADL, activities of daily living; ALG, anti-lymphocyte globulin; AZA, azathioprine; CsA, Ciclosporin A; CK, Creatine Kinase; DM, dermatomyositis; Dex, 
dexamethasone; EMG, electromyogram; ETAN, etanercept; IL-1Ra, Interleukin 1 Receptor antagonist; IV, intravenous; IVIg, intravenous immunoglobulin; 
MEFT, muscle endurance and function test; MMT, manual muscle testing; MTX, methotrexate; PBO, placebo; PEX, plasma exchange; PM, polymyositis; Pred, 
prednisolone; RCT, randomized controlled trial 
  
Table 2. Baseline characteristics of patients in the included studies 
 
 
Study Cases, n Age, mean Female, % Disease duration, 
months 
CK, U//L Muscle strength 
Corticosteroids 
van de Vlekkert 
et al. 2010 
62 
Pred: 32 
Dex: 30 
 
Pred: 48 
Dex: 49 
65% 
Pred: 59% 
Dex: 67% 
 
Pred: 3.5 
Dex: 4.5 
 
Pred: 4074 
Dex: 2749 
MMT15 (max 140) 
Pred: 128 
Dex: 127 
Immunosuppressants 
Bunch et 
al.1980 
16 
AZA: 8 
PBO: 8 
 
AZA: 38.3 
PBO: 40.9 
69% 
AZA: 63% 
PBO: 75% 
 
AZA: 8.6 
PBO: 9.6 
 
AZA: 2463 
PBO: 809 
MMT18 (max 90) 
AZA: -39.1 
PBO: -27.1 
Hollingworth et 
al. 1982 
14 Pred: 50 
ALG/AZA/Pred: 55 
ALG/AZA/Pred 
Pred: 50% 
ALG/AZA/Pred: 
57% 
Pred: 11 
ALG/AZA/Pred: 14 
ALG/AZA/Pred failure: 
Data not shown Data not shown 
  
failure: 42 ALG/AZA/Pred 
failure: 60% 
40 
Villalba et al. 
1998 
30 
MTX/AZA: 15 
IV MTX: 15 
 
MTX/AZA: 41.5 
IV MTX: 40.1 
80% 
MTX/AZA: 80% 
IV MTX: 80% 
 
MTX/AZA: 45.1 
IV MTX: 34.9 
 
MTX/AZA: 4023 U/l 
IV MTX: 2337 U/l 
MMT16 (max 80) 
MTX/AZA: 58.1 
IV MTX: 56.3 
Vencovsky et 
al. 2000 
36 
MTX: 17 
CsA: 19 
 
MTX: 38.4 
CsA: 42.6 
64% 
MTX: 82% 
CsA: 47% 
 
MTX: 30 
CsA: 28 
 
MTX: 2535 
CsA: 1629 
MEFT (max 56) 
MTX: 24.1 
CsA:  30.5 
Ibrahim et al. 
2014 
58 
MTX/CsA:15 
MTX:12 
CsA:16 
PBO:15 
 
MTX/CsA:55 
MTX:50 
CsA:48 
PBO:49 
 
MTX/CsA:73 
MTX:83 
CsA:63 
PBO:60 
 
MTX/CsA:24.36 
MTX:21.96 
CsA:24.24 
PBO:30.84 
 
MTX/CsA:310 
MTX:104 
CsA:326 
PBO:309 
MMT 
MTX/CsA:63 
MTX:68 
CsA:66 
PBO:65 
Biologic agents 
The Muscle 
Study Group. 
16 
ETAN: 11 
 
ETAN: 43.4 
63% 
ETAN: 55% 
 
ETAN: 13.2 
 
ETAN: 821 
MMT26 (max 13) 
ETAN: 4.5 
  
2011 PBO: 5 PBO: 44.2 PBO: 80% PBO: 26.4 PBO: 1098 PBO: 4.3 
Oddis et al. 
2013 
 
152 
Early RTX:73 
Late RTX: 79 
 
(includes JDM) 
Early RTX:43 
Late RTX: 40 
(includes JDM) 
Early RTX:71 
Late RTX: 75 
(includes JDM) 
Early RTX:62.4 
Late RTX: 64.8 
Similar in both groups 
but presented at 
times upper limit 
normal 
(includes JDM) 
MMT-8 ratio 
Early RTX: 71 
Late RTX: 71.7 
Other 
Dalakas et al. 
1993 
15 
IVIg: 8  
PBO: 7 
36 67% IVIg: 46.8 
PBO: 45.6 
IVIg: 1076 U/l 
PBO: 842 U/l 
MMT18 (max 90) 
IVIg: 76.6 (+/-59.7) 
PBO: 78.6 (+/-6.3) 
Miyasaka et al. 
2011 
26 
IVIg: 12 
PBO: 14 
 
IVIg: 50.6 
PBO: 48.1 
77% 
IVIg: 92% 
PBO: 64% 
IVIg: 42% <6/12, 0% 6-
12/12, 58% > 1 year 
PBO: 21% <6/12, 29% 
6-12/12, 50% >1 year 
Data not shown MMT18 (max 90) 
IVIg: 61.8 
PBO: 64.7 
Miller et al. 
1992 
39 
PEX: 13 
Leukapheresis: 
 
PEX: 41.5 
Leukapheresis: 41.4 
72% 
PEX: 69% 
Leukapheresis: 
PEX: 37.2 
Leukapheresis: 46.8 
Sham: 28.8 
Reported as similar, 
but data not shown 
Reported as 
similar, but data 
not shown 
  
13 
Sham: 13 
Sham: 40.2 77% 
Sham: 69% 
 
ALG, anti-lymphocyte globulin; AZA, azathioprine; CsA, ciclosporin A; Dex, dexamethasone; IV, intravenous; IVIg, intravenous immunoglobulin; MEFT, muscle 
endurance and function test; MMT, manual muscle testing; MTX, methotrexate; PBO, placebo; PEX, plasma exchange; Pred, prednisolone; RTX, rituximab 
  
Table 3. Summary of the main findings in each of the included studies 
Studies analysed different immunosuppressive regimens and outcome measures. Most suggested a potential benefit from the addition of a second-line agent, 
although this was not always statistically significant. 
 
St
u
d
y 
Muscle strength Physical function CK,  U/L Patient/ 
physician 
global 
Withdrawals Conclusion 
Corticosteroids 
va
n
 d
e 
V
le
kk
er
t 
et
 a
l. 
2
0
1
0
 MMT15 
Pred: 135 (+7) 
Dex: 136 (+9) 
SF-36 (physical 
component, max 
100) 
Pred: 40 
Dex: 39 
 
Pred: 100 
Dex: 197 
NR  
Pred: 17 withdrawals 
Dex: 21 withdrawals 
Dex not superior to Pred, but 
causes less adverse effects 
Immunosuppressants 
B
u
n
ch
 e
t 
a
l. 
1
9
8
0 
MMT18 
Pred + AZA: +6.5 
NR Mean days to 
normal CK 
NR PBO: 1 for inefficacy, 1 
for unrelated reasons 
No benefit in adding AZA to 
pred 
  
Pred + PBO: +1.1 
NS 
measured 
Pred + AZA: 69.4 
Pred + PBO: 53.5 
NS 
AZA: 2 for toxicity (GI, 
pneumonitis) 
B
u
n
ch
 e
t 
a
l. 
19
8
1
 
Improvement in 
functional 
gradea 
Pred + AZA: -1.5b 
Pred + PBO: -
0.5b 
NR Pred + AZA: 49.1 
(2463) 
Pred + PBO: 73.8 
(809) 
NR AZA: 2 temporarily 
stopped for toxicity 
(CMV, leukopenia) 
AZA group stronger and 
required less pred 
H
o
lli
n
gw
o
rt
h
 e
t 
a
l. 
1
9
8
2
 
Minimal 
improvement in 
IIS group 
NR More marked 
reduction in CK in 
IIS group 
NR NR Trend toward additional 
benefit with IIS 
V
ill
al
b
a 
et
 a
l. 
1
9
9
8 
MMT 
NS trend 
towards 
ADL score 
NS trend towards 
improvement in 
NR NR MTX/AZA: 11 
IV MTX: 11 
Trend toward additional 
benefit with combination 
therapy 
  
improvement in 
MTX/AZA group 
MTX/AZA group 
V
en
co
vs
ky
 e
t 
a
l. 
2
0
0
0
 MEFT 
Significant 
improvement in 
both groups^ 
NR Significant 
decrease in both 
groups by 6 
monthsb 
Significant 
improveme
nt in patient 
global^ 
NR Addition of MTX or CsA 
confers benefit 
MTX cheaper, less toxic and 
better tolerated 
Ib
ra
h
im
 e
t 
al
. 2
0
1
4
 
MMT 
Significant 
improvement 
but lost in 
intention to 
treat analysis 
FRS 
Significant 
improvement but 
lost in intention 
to treat analysis 
No difference in 
intervention 
groups on 
intention to treat 
analysis 
NR MTX/CsA:1 lost to 
follow-up, 2 toxicity, 1 
other 
MTX: 3 lost to follow-up, 
1 progression, 1 toxicity 
and 1 patient choice 
CsA: 1 lost to follow-up, 
1 toxicity, 3 patient 
choice 
PBO: 2 lost to follow-up, 
Improvements in disease 
activity measures but no 
difference in intention to treat 
analysis and therefore of 
questionable benefit. 
  
2 progression, 2 toxicity 
Biologic agents 
Th
e 
M
u
sc
le
 S
tu
d
y 
G
ro
u
p
 
2
0
1
1 
MMT26 
ETAN: 0.22 
PBO: 0.27 
HAQ 
ETAN: -0.44 
PBO: -0.34 
 
Log[CK] 
ETAN: -0.1 
PBO: 0.16 
 
ETAN: -1.7/-
2.0 
PBO: -2.1/-
1.0 
ETAN: 1 (lost to follow-
up) 
PBO: 1 (lack of benefit) 
No significant difference in 
outcomes, but ETAN appears 
safe and has a steroid-sparing 
effect 
O
d
d
is
 e
t 
al
. 
2
0
1
3 
MMT-8 
Improvement 
but no 
significant 
improvement 
between RTX 
early or late 
groups 
HAQ 
Improvement but 
no significant 
improvement 
between RTX 
early or late 
groups 
Improvement but 
no significant 
improvement 
between RTX 
early or late 
groups 
Improveme
nt but no 
significant 
improveme
nt between 
RTX early or 
late groups 
5: 1 due to toxicity (late 
RTX group) 
83% of patients met DOI but 
no significant differences 
between two treatment arms. 
Steroid sparing effect 
  
Other 
D
al
ak
as
 e
t 
a
l. 
1
9
93
 
MMT 
IVIg: +8.0b 
PBO: +0.0 
ADL score 
Reported in 
responders only 
(+35) 
NR NR NR Benefit in refractory DM 
M
iy
as
ak
a 
et
 a
l. 
2
0
11
 
 
MMT18: 
IVIg: +11.8b 
PBO: +9.9b 
ADL score (max 
45) 
IVIg: +7.3 
PBO: +4.0 
Log[CK] 
IVIg: -1.16b 
PBO: -1.27b 
NR IVIg: 1 
PBO: 0 
Safe in steroid-resistant 
DM/PM, but no better than 
placebo 
M
ill
er
 e
t 
a
l. 
1
9
9
2
 
MMT 
No significant 
change in either 
group 
ADL score 
No significant 
change in any 
group 
Significant 
decrease in PEX 
and leukapheresis 
groups, not sham 
group 
NR NR No benefit 
 
a. Grades 1 through 6: 1 = normal to 6 = cannot walk   
b. statistically significant p<0.05 
  
ADL, activities of daily living; ALG, anti-lymphocyte globulin; ALT, alanine aminotransferase; AST,aAspartate aminotransferase; AZA, azathioprine; CsA, 
ciclosporin A; CK, creatine kinase; DOI, definition of improvement; DM, dermatomyositis; EMG, electromyogram; IIS, intensive immunosuppression (ALG + 
AZA + Pred); IV, intravenous; IVIg, intravenous immunoglobulin; LDH;, lactate dehydrogenase; MEFT, muscle endurance and function test; MMT, manual 
muscle testing; MTX, methotrexate; NR, not reported; NS, not significant; PBO, placebo; PEX, plasma exchange; PM, polymyositis; Pred, prednisolone; RTX, 
rituximab 
 
 
